新型氧载体基于磁共振成像分析在大血管闭塞犬模型中减缓梗死进展
研究在犬血栓栓塞性大血管闭塞卒中模型中,于卒中发作后45至60分钟静脉给予新型氧载体OMX-IS或安慰剂,用灌注加权磁共振成像区分快速与缓慢进展者,并用系列弥散加权磁共振成像量化梗死演变。结果显示,在快速进展者中OMX-IS显著减缓梗死进展约1小时并减小最终标准化梗死体积(对照组0.99 vs OMX-IS组0.88,P<0.0001);在缓慢进展者中延迟约45分钟但未达统计学显著(P=0.09),最终梗死体积无显著差异(OMX-IS组0.93 vs 对照组0.95,P=0.34)。
要点
- 在快速进展的犬大血管闭塞卒中模型中,OMX-IS使梗死进展减缓约1小时(P<0.0001)。
- 快速进展者最终标准化梗死体积对照组0.99 vs OMX-IS组0.88(P<0.0001)。
- 缓慢进展者梗死进展延迟约45分钟未达统计学显著(P=0.09)。
核心结论
- 静脉给予新型氧载体是延迟缺血性卒中后梗死进展的有前景方法,尤其适用于无法及时接受确定性再灌注治疗的大血管闭塞卒中患者。
研究设计与样本
- 在建立犬血栓栓塞性大血管闭塞卒中模型后,于卒中发作后45至60分钟给予OMX-IS或安慰剂,用灌注加权磁共振成像将动物分为快速与缓慢进展者,系列弥散加权磁共振成像随访至5小时,死后组织学确认最终梗死体积。
主要发现
- 快速进展者中,OMX-IS治疗使梗死进展减缓约1小时(P<0.0001),最终标准化梗死体积对照组0.99 vs OMX-IS组0.88(P<0.0001)。
- 缓慢进展者中,OMX-IS治疗使梗死进展延迟约45分钟,但未达统计学显著(P=0.09);最终标准化梗死体积OMX-IS组0.93 vs 对照组0.95(P=0.34),无显著差异。
- 死后组织学确定的梗死体积与磁共振成像定义的缺血病灶体积高度一致(偏倚1.33%[95%CI,-15%至18%])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tissue hypoxia plays a critical role in the events leading to cell death in ischemic stroke. Despite promising results in preclinical and small clinical pilot studies, inhaled oxygen supplementation has not translated to improved outcomes in large clinical trials. Moreover, clinical observations suggest that indiscriminate oxygen supplementation can adversely affect outcome, highlighting the need to develop novel approaches to selectively deliver oxygen to affected regions. This study tested the hypothesis that intravenous delivery of a novel oxygen carrier (Omniox-Ischemic Stroke [OMX-IS]), which selectively releases oxygen into severely ischemic tissue, could delay infarct progression in an established canine thromboembolic large vessel occlusion stroke model that replicates key dynamics of human infarct evolution. METHODS: After endovascular placement of an autologous clot into the middle cerebral artery, animals received OMX-IS treatment or placebo 45 to 60 minutes after stroke onset. Perfusion-weighted magnetic resonance imaging was performed to define infarct progression dynamics to stratify animals into fast versus slow stroke evolvers. Serial diffusion-weighted magnetic resonance imaging was performed for up to 5 hours to quantify infarct evolution. Histology was performed postmortem to confirm final infarct size. RESULTS: In fast evolvers, OMX-IS therapy substantially slowed infarct progression (by ≈1 hour, P<0.0001) and reduced the final normalized infarct volume as compared to controls (0.99 versus 0.88, control versus OMX-IS drug, P<0.0001). Among slow evolvers, OMX-IS treatment delayed infarct progression by approximately 45 minutes; however, this did not reach statistical significance (P=0.09). The final normalized infarct volume also did not show a significant difference (0.93 versus 0.95, OMX-IS drug versus control, P=0.34). Postmortem histologically determined infarct volumes showed excellent concordance with the magnetic resonance imaging defined ischemic lesion volume (bias: 1.33% [95% CI, -15% to 18%). CONCLUSIONS: Intravenous delivery of a novel oxygen carrier is a promising approach to delay infarct progression after ischemic stroke, especially in treating patients with large vessel occlusion stroke who cannot undergo definitive reperfusion therapy within a timely fashion.
引用
- Shazeeb MS, King RM, Anagnostakou V, et al. Novel Oxygen Carrier Slows Infarct Growth in Large Vessel Occlusion Dog Model Based on Magnetic Resonance Imaging Analysis. Stroke. 2022. PMID: 35306836. doi:10.1161/STROKEAHA.121.036896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。